The FDA's drug approvals database lists a supplement, dated 1 November, to the new drug application for Ozurdex, AbbVie's intravitreal dexamethasone implant used for macular oedema and uveitis. The entry does not state what the supplement changes; such supplements usually cover labelling, manufacturing or packaging.
The item reached this desk because the regulatory sweep matches corticosteroid products. It is an ophthalmic implant and has no bearing on inhaled or systemic steroid prescribing for lung disease.
- No change to respiratory prescribing follows from this notice.
- Ask patients on steroid eye implants about them when totting up total corticosteroid exposure, as standard practice.
- Refer questions about the implant itself to ophthalmology.
Why it matters
It is listed so the regulatory record stays complete, not because it alters care.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free